ACADIA Pharmaceuticals stock has delivered a solid 38.5% gain over the past five years, yet recent short term returns have been softer. This puts more attention on whether the current valuation still looks appealing or is starting to run ahead of the story.

• Over five years, ACADIA Pharmaceuticals has returned 38.5%, which suggests long term holders have been rewarded despite more modest moves in recent months.
• Progress with dementia related psychosis drug candidate ACP-204 can support investor expectations for future revenue, while competition from larger pharmaceutical companies working on similar therapies may limit how much investors are willing to pay for the stock.
• On Simply Wall St's broader checks, ACADIA Pharmaceuticals screens as relatively cheap, with the company passing 5 out of 6 valuation tests here.

The issue now is whether the current share price around US$25.61 still leaves enough valuation upside for new investors after that multi year gain.

Does ACADIA Pharmaceuticals Look Undervalued on Earnings?

The P/E ratio is a useful way to sanity check what you are paying for each dollar of ACADIA Pharmaceuticals earnings today. On this measure, ACADIA trades on about 11.7x earnings, which is well below the broader biotechs sector average of around 17.0x and also below the peer group average of roughly 57.0x.

The fair P/E multiple from Simply Wall St’s model is about 19.0x, which is higher than where the stock currently trades and indicates a discount on this earnings yardstick. Recent interest in dementia related psychosis treatments, including ACADIA’s ACP-204 program, has added attention to the story. However, the market is still pricing ACADIA at a lower earnings multiple than both the industry and that modelled fair level.

On the P/E multiple alone, ACADIA Pharmaceuticals stock appears undervalued relative to both its sector and the modelled fair ratio.

The ACADIA Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the P/E discussion for ACADIA Pharmaceuticals leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today’s price. Each narrative ties a fair value estimate to a specific mix of potential catalysts and risks for ACADIA Pharmaceuticals' business, so you can track over time which broad storyline appears to align with reality.

Community views on ACADIA Pharmaceuticals sit far apart, with one camp seeing cautious optionality and the other focusing on concentrated risk.

Bull case: 11% undervalued

"Any evidence of sustained diversification or improved operating leverage could shift sentiment quickly..."

Bear case: 24% overvalued

"ACADIA remains heavily dependent on a narrow product portfolio dominated by NUPLAZID and DAYBUE, leaving the company acutely exposed to patent cliffs, competitive threats from generics or biosimilars, and loss of exclusivity events after 2038..."

Do you think there's more to the story for ACADIA Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For ACADIA Pharmaceuticals, the current picture leans toward undervalued on traditional earnings multiples, especially against sector and peer averages. The broader valuation checks also line up on the supportive side, which gives that P/E discount more weight than a single quirky signal. What matters most from here is whether ACADIA can broaden its product base and sustain earnings quality so that the market feels comfortable re-rating the stock rather than keeping a discount in place for concentration and competitive risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.